Edition:
India

Homology Medicines Inc (FIXX.OQ)

FIXX.OQ on NASDAQ Stock Exchange Global Select Market

20.00USD
23 Apr 2018
Change (% chg)

$-0.40 (-1.96%)
Prev Close
$20.40
Open
$20.61
Day's High
$20.70
Day's Low
$19.78
Volume
13,162
Avg. Vol
--
52-wk High
$24.40
52-wk Low
$16.12

Summary

Name Age Since Current Position

Arthur Tzianabos

53 2016 President, Chief Executive Officer, Director

Sam Rasty

Chief Operating Officer

Albert Seymour

Chief Scientific Officer

Steven Gillis

64 Director

Kush Parmar

36 Director

Biographies

Name Description

Arthur Tzianabos

Dr. Arthur Tzianabos Ph.D. is the President, Chief Executive Officer, Director of the company. Arthur Tzianabos brings 25 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. During his nine-year tenure at Shire, he played an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire's product pipeline. Dr. Tzianabos joins Homology Medicines from OvaScience where he served as President and CSO and was responsible for translating breakthrough science into new treatments, which included the commercial launch of the company's first product. Earlier in his career, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

Sam Rasty

Dr. Sam Rasty is the Chief Operating Officer of the company. Sam Rasty brings together more than 20 years of scientific, clinical, commercial, strategy and business development experience in the life sciences sector across multiple specialty therapeutic areas, rare diseases and technology platforms, spanning from start-up biotechnology to global large pharmaceutical companies. Most recently he was Vice President and Head of New Products at the Rare Diseases Business Unit of Shire Pharmaceuticals. In this role, he was positioned at the intersection of Commercial, R&D and Business Development to drive the strategy for growth of the rare disease business through internal product development and external licensing and acquisitions. Prior to joining Shire, Dr. Rasty's responsibilities included Corporate Development and Strategic Marketing at Endo Pharmaceuticals as part of the team that drove diversification of Endo's business through a series of licensing and M&A transactions, and Global Commercial Strategy and Portfolio Management at GlaxoSmithKline within the global R&D organization. Earlier in his career, he held various roles of increasing responsibility in business development and R&D at small, private biotechnology companies. Dr. Rasty holds a Ph.D. in Biochemistry from Louisiana State University, completed his postdoctoral training in Molecular Genetics/Gene Therapy at the University of Pittsburgh School of Medicine and received an M.B.A. from Villanova University.

Albert Seymour

Mr. Albert Seymour is the Chief Scientific Officer of the company. Mr. Seymour has spent more than 20 years coupling the discipline of Human Genetics with Pharmaceutical R&D resulting in the delivery of multiple therapeutic programs into development. Most recently he was the Senior Vice President and Global Head of Research and Nonclinical Development at Shire Pharmaceuticals where he led a team responsible for the delivery of a sustained flow of rare disease therapeutics from idea to IND and supported the full R&D portfolio in the areas of toxicology, bioanalytics, and Drug Metabolism and Pharmacokinetics. Prior to his role as Global Head of Research and Nonclinical Development, Dr. Seymour served as the VP and Head of Drug Discovery and Translational Research at Shire where he doubled the rare disease discovery portfolio in three years. Subsequent to joining Shire, he spent 14 years at Pfizer leading a team in the application of human genetics and computational biology to discover and develop therapeutics and pharmacogenomics strategies in diabetes, inflammatory diseases, and oncology. Dr. Seymour received his undergraduate degree in Biology from the University of Delaware and M.S. degree in Molecular Biology from Johns Hopkins University where he focused on the molecular genetics of cancer. He received his Ph.D. and post-doctoral training in Human Genetics at the University of Pittsburgh.

Steven Gillis

Dr. Steven Gillis Ph.D., is the Director of the company. Dr. Steven Gillis is a Managing Director with ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH's biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corp. and served as CEO from its inception and as its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, he served as Immunex's Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex's R&D subsidiary. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein), as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis is a director of Shire Pharmaceuticals, Allozyne, Pulmatrix, Codiak Biosciences, Faraday Pharmaceuticals, Just Biotherapeutics, VLST, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines, and PhaseRx. He received a B.A. from Williams College and a Ph.D. from Dartmouth College.

Kush Parmar

Dr. Kush M. Parmar M.D., Ph.D., is the Director of the company. Dr. Kush M. Parmar is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Arvinas, Audentes, Homology and scPharmaceuticals. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and was Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO) and Pulmatrix (NASDAQ: PULM). He serves on the Scientific Advisory Council of Princeton University's Department of Molecular Biology and for the Grace Wilsey Foundation and is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow at Harvard Medical School and completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.